Drugs / Cryoprecipitate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05638581 | Jul 2023 → Dec 2026 expected | — | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 3 | NCT04704869 | Jan 2017 → Dec 2021 | — | Bryan Cotton | Completed | No outcome recorded |
| Phase 3 | NCT00916656 | Oct 2009 → Mar 2014 | congenital afibrinogenemia | CSL Behring | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03508141 Comparator | Jul 2018 → Jun 2021 | blood coagulation disease, hemorrhagic disease | Gold Coast Hospital and Health Service | Unknown | No outcome recorded |
| Phase 2 | NCT01187225 Comparator | Aug 2010 → Jan 2011 | blood coagulation disease | University of Sao Paulo | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06617897 Comparator | Oct 2024 → Sep 2027 expected | acquired coagulation factor deficiency | CSL Behring | Recruiting | No outcome recorded |
| Phase 3 | NCT03932240 Comparator | Aug 2019 → Apr 2021 | vascular hemostatic disease | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT03444324 Comparator | Apr 2018 → Sep 2023 | coagulation protein disease | Biotest | Completed | No outcome recorded |
| Phase 3 | NCT03037424 Comparator | Feb 2017 → Nov 2018 | acquired coagulation factor deficiency | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04376762 Comparator | Oct 2021 → Mar 2023 | hemorrhagic disease, juvenile Huntington disease | University of Virginia | Completed | No outcome recorded |
| Phase 4 | NCT03045068 Background | Apr 2017 → Oct 2018 | cardiac rhythm disease, cardiac valvular defect | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03014700 Comparator | Mar 2016 → Apr 2018 | congenital heart disease | Stanford University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cryoprecipitate | “Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.” NCT05638581 ↗11“Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo)” NCT03444324 ↗ |
| Action | Restore | “fibrinogen replacement with cryoprecipitate or fibrinogen concentrate” PMID 31634905 ↗ Nov 2019 |
| Modality | Protein / enzyme biologic | “Biological: Cryoprecipitate” NCT03014700 ↗ |
| Route | Intravenous | “FFP/Cryo was administered intravenously” NCT03444324 ↗ |